Is NiceRx a Sogroya coupon provider?
We are a service provider that helps eligible individuals access the Sogroya patient assistance program. That means that we do not offer printable Sogroya manufacturer coupons, Sogroya discounts, or free Sogroya samples. We are not a Sogroya coupon provider or a Sogroya discount card. Our service extends to assisting eligible individuals to access the medications they need through patient assistance programs.
Sogroya patient assistance program
Patient assistance programs are typically sponsored by pharmaceutical companies and provide free or discounted medications to individuals with low income who are uninsured or under-insured and meet the eligibility criteria that vary by program. There are currently no known patient assistance programs for this medication.
Can NiceRx help me get Sogroya cheaper if I have insurance?
How much does Sogroya cost without insurance?
Sogroya’s cost without insurance will vary depending on where you buy it. With NiceRx you will pay a flat monthly fee of $49, regardless of the retail price of your medication.
How much does Sogroya cost with insurance?
The copay for Sogroya with insurance depends on the terms of your healthcare plan. To find out how much this is, your healthcare provider or pharmacist will be able to calculate your copay with your current insurance.
What is Sogroya?
Sogroya is an FDA (U.S. Food and Drug Administration) approved medication manufactured by Novo Nordisk. It is a human growth hormone analog used for the replacement of endogenous growth hormone in adult patients with growth hormone deficiency (GHD).
What doses of Sogroya are available?
Sogroya is available in injection form, in the following doses: 10 mg/1.5 mL single-patient-use prefilled pen.
Administer Sogroya as a subcutaneous injection once weekly to the abdomen or thigh with a regular rotation of injection sites to avoid lipohypertrophy/lipoatrophy. Begin treatment with a dosage of 1.5 mg once weekly for the treatment of naïve patients or patients switching from daily growth hormone. Titrate the dose depending on response and serum insulin-like growth factor 1 (IGF-1) concentrations.
See the full prescribing information for further information about the safe and effective use of Sogroya, dosage recommendations in patients 65 years of age and older, patients with hepatic impairment, and women receiving oral estrogen. Always speak with your healthcare provider about any changes to your dose so they can monitor and evaluate your condition.
Sogroya active ingredients
The active ingredient in Sogroya is somapacitan, which acts in the same way as the human growth hormone. Sogroya binds to albumin, a protein in the blood which makes it stay in the body for longer. This allows somapacitan-beco to be given as weekly Sogroya, unlike other growth hormone replacement therapies which are given every day.
Sogroya side effects
The most common side effects of Sogroya in clinical trials compared to placebo include:
- Back pain, arthralgia
- Dyspepsia, vomiting
- Sleep disorder
- Peripheral edema
- Adrenal insufficiency
- Increased blood creatine phosphokinase
- Weight gain
In rare instances, Sogroya can cause more serious side effects. These can include:
- Increased risk of neoplasm
- Glucose intolerance and diabetes mellitus
- Intracranial hypertension
- Fluid retention
- Lipohypertrophy/lipoatrophy – rotate injection sites on a regular basis
Your doctor will assess the benefits of using Sogroya against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions to Sogroya to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Sogroya drug interactions
Sogroya can interact with other medications. These include:
- Replacement glucocorticoid treatment – those treated for hypoadrenalism may require an increase in their maintenance or stress doses
- Cytochrome P450-metabolized drugs
- Oral estrogen – larger doses of Sogroya may be required
- Insulin and other hypoglycemic agents
This list is not exhaustive and other prescription drugs may interact with Sogroya.
You should not use Sogroya if you:
- Are allergic to the active ingredient somapacitan-beco
- Are allergic to any of the other ingredients in Sogroya
- Have an acute critical illness
- Have active malignancy
- Have active proliferative or severe non-proliferative diabetic retinopathy
Talk to your doctor before using Sogroya if you:
- Are taking any of the medications that could interact with Sogroya
- Are pregnant or are planning to become pregnant
- Are breastfeeding or are planning to breastfeed
Sogroya is the trademark brand name for somapacitan-beco manufactured by Novo Nordisk A/S. A generic version of somapacitan-beco is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Sogroya savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.